AGLE - アエグリア・バイオセラピュ―ティクス （Aeglea BioTherapeutics Inc.）

AUSTIN, Texas, March 17, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the company granted non-qualified…

Aeglea BioTherapeutics (NASDAQ: AGLE ) brought in sales totaling $168 thousand during Q4 according to data provided by Benzinga Pro . However, earnings decreased 3.22%, resulting in a loss of $18.82 million. In Q3, Aeglea BioTherapeutics brought in $174 thousand in sales but lost $18.23 million in earnings. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign … Full story available on Benzinga.com

The following slide deck was published by Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics press release (AGLE): FY GAAP EPS of -$0.99 beats by $0.03.Revenue of $2.33M (-87.6% Y/Y) beats by $0.1M.As of December 31, 2022, Aeglea had available cash,…

Jeffrey Goldberg , experienced biotech executive, appointed president and CEO; further strengthened senior management team with appointments of chief medical officer and chief product officer $57.3 million of cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2022 , which is expected to fund operations into the fourth quarter of 2023 AUSTIN, Texas , March 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE ), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the fourth quarter and full year 2022, and provided program updates. "Since joining the company, I have been impressed by the programs and the potential impact that they may have on patient lives. In 2023, we are highly focused on execution, specifically the generation of data from our pegtarviliase Phase 1/2 clinical trial in Classical Homocystinuria and, assuming success with those data, preparations to advance into a potential pivotal trial," said Jeffrey Goldberg , president and chief executive officer of Aeglea. "We are also continuing to work with our partner Immedica Pharma AB to support the EMA [European Medicines Agency] review process for the Marketing Authorization Application for pegzilarginase for the treatment of Arginase 1 Deficiency.

Streamlining of organization to focus on near-term deliverables for pegtarviliase in Homocystinuria and long-term value creation Cortney Caudill, M.B.A., has been promoted to the newly created role… | January 6, 2023

Streamlining of organization to focus on near-term deliverables for pegtarviliase in Homocystinuria and long-term value creation Cortney Caudill, M.B.A., has been promoted to the newly created role of chief product officer to increase focus and efficiency in the advancement of clinical…

During the last session, Aeglea BioTherapeutics Inc. (NASDAQ:AGLE)’s traded shares were 0.62 million, with the beta value of the company hitting 1.74. At the end of the trading day, the stock’s price was $0.45, reflecting an intraday gain of 25.99% or $0.09. The 52-week high for the AGLE share is $4.83, that puts it down … As The Stock Falls By -90.53% Year-To-Date, Aeglea BioTherapeutics Inc. (NASDAQ: AGLE)’S Stock Continues To Progress In 2022 Read More »

As of Tuesday, Aeglea BioTherapeutics Inc.’s (NASDAQ:AGLE) stock closed at $0.39, up from $0.36 the previous day. While Aeglea BioTherapeutics Inc. has overperformed by 8.07%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AGLE fell by -90.88%, with highs and lows ranging from $4.83 to $0.34, […]

A share of Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) closed at $0.38 per share on Friday, down from $0.38 day before. While Aeglea BioTherapeutics Inc. has underperformed by -0.90%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AGLE fell by -89.61%, with highs and lows ranging from $4.83 […]

During the last session, Aeglea BioTherapeutics Inc. (NASDAQ:AGLE)’s traded shares were 0.36 million, with the beta value of the company hitting 1.63. At the end of the trading day, the stock’s price was $0.49, reflecting an intraday loss of -7.58% or -$0.04. The 52-week high for the AGLE share is $8.50, that puts it down … Is Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) Stock On Course For Another Boom Or Bust? Read More »

Aeglea BioTherapeutics Inc. (NASDAQ:AGLE)’s traded shares stood at 0.39 million during the last session, with the company’s beta value hitting 1.64. At the close of trading, the stock’s price was $0.49, to imply a decrease of -1.94% or -$0.01 in intraday trading. The AGLE share’s 52-week high remains $8.50, putting it -1634.69% down since that … Following A -7.79% Weekly Decline, Is It Still A Buy For Aeglea BioTherapeutics Inc. (NASDAQ: AGLE)? Read More »

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Enthralling stocks: Tyme Technologies, Inc. (NASDAQ:TYME -12.92%), Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE -5.77%) appeared first on Stocks Equity .

Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) price closed lower on Friday, September 02, dropping -2.20% below its previous close. A look at the daily price movement shows that the last close reads $0.53, with intraday deals fluctuated between $0.51 and $0.5312. The company’s 5Y monthly beta was ticking 1.94. Taking into account the 52-week price action we … Where Do Analysts Think The Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) Is Going Read More »

In last trading session, Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) saw 1.11 million shares changing hands with its beta currently measuring 1.80. Company’s recent per share price level of $0.53 trading at $0.01 or 1.66% at ring of the bell on the day assigns it a market valuation of $32.85M. That closing price of AGLE’s stock is … After A 1.66% Gain In Share Price, Is Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) A Better Trade Than Others? Read More »